Aura Biosciences, Inc. (AURA) has a negative trailing P/E of -3.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -26.26%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -1,787.0 | 0.00 | 1,405.75 | 0.00 | - |
| 2020 | -19.5 | 0.00 | 22.33 | 0.00 | - |
| 2021 | -14.1 | -0.26 | 3.26 | 0.00 | - |
| 2022 | -5.3 | -0.22 | 1.61 | 0.00 | - |
| 2023 | -4.6 | 3.00 | 1.55 | 0.00 | - |
| 2024 | -4.7 | 0.50 | 2.69 | 0.00 | - |
| 2025 | -3.1 | -5.42 | 2.40 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.83 | $0.00 | $-24.21M | - |
| 2020 | $-0.76 | $0.00 | $-22.21M | - |
| 2021 | $-1.18 | $0.00 | $-34.42M | - |
| 2022 | $-1.91 | $0.00 | $-57.23M | - |
| 2023 | $-1.93 | $0.00 | $-76.41M | - |
| 2024 | $-1.75 | $0.00 | $-86.92M | - |
| 2025 | $-1.76 | $0.00 | $-106.19M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.82 | $-1.95 – $-1.73 | $19.2M | $13.89M – $24.5M | 3 |
| 2027 | $-1.78 | $-1.95 – $-1.70 | $21.02M | $15.21M – $26.83M | 3 |
| 2028 | $-1.57 | $-1.74 – $-1.39 | $34.06M | $33.78M – $34.35M | 2 |
| 2029 | $-1.04 | $-1.42 – $-0.67 | $108.38M | $78.41M – $138.29M | 1 |
| 2030 | $-0.60 | $-0.82 – $-0.38 | $195M | $141.07M – $248.8M | 1 |
